(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 December 2014 (18.12.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/198852 A3

(51) International Patent Classification:
*A61K 35/76* (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/EP2014/062284

(22) International Filing Date:
12 June 2014 (12.06.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

| | | |
|---|---|---|
| 1310698.4 | 14 June 2013 (14.06.2013) | GB |
| 1405140.3 | 22 March 2014 (22.03.2014) | GB |
| 1406509.8 | 10 April 2014 (10.04.2014) | GB |


(71) Applicant: **PSIOXUS THERAUPEUTICS LIMITED** [GB/GB]; 154B Milton Park, Abingdon Oxfordshire OX14 4SD (GB).

(72) Inventors: **BEADLE, John, William**; 154B Milton Park, Abingdon Oxfordshire OX14 4SD (GB). **FISHER, Kerry**; 154B Milton Park, Abingdon Oxfordshire OX14 4SD (GB). **WILKINSON BLANC, Christine**; 154B Milton Park, Abingdon Oxfordshire OX14 4SD (GB).

(74) Agent: **HAMBLETON, Bernadette**; Sterling IP, Orion House, Bessemer Road, Welwyn Garden City Hertfordshire AL7 1HH (GB).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17**:

— *of inventorship (Rule 4.17(iv))*

**Published**:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
2 April 2015

(54) Title: A DOSING REGIME AND FORMULATIONS FOR TYPE B ADENOVIRUSES

(57) Abstract: The present disclosure provides a method of treating a human patient comprising the steps of: systemically administering multiple doses of a parenteral formulation of a replication capable oncolytic adenovirus of subgroup B in a single treatment cycle, wherein the total dose given in each dose is in the range of $1x10^{10}$ to $1x10^{14}$ viral particles, and wherein each dose of virus is administered over a period of 1 to 90 minutes, for example at a rate of viral particle delivery in the range of $2x10^{10}$ particles per minute to $2x10^{12}$ particles per minute. The disclosure further extends to formulations of the said oncolytic adenoviruses and combination therapies of the viruses and formulations with other therapeutic agents.

WO 2014/198852 A3